Daniel P. Morin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniel P. Morin has a total of 454 co-authors. Here are the top co-authors by number of shared publications:
Sammy Khatib
Department of Cardiology, Division of Electrophysiology Ochsner Medical Center Louisiana New Orleans USA
15 shared publicationsMichael L. Bernard
Department of Cardiology, Division of Electrophysiology Ochsner Medical Center Louisiana New Orleans USA
13 shared publicationsPaul A. Rogers
Department of Cardiology, Division of Electrophysiology Ochsner Medical Center Louisiana New Orleans USA
11 shared publications- Carl J. Lavie
John Ochsner Heart and Vascular Institute, Ochsner Clinical School-The University of Queensland School of Medicine, New Orleans, LA
10 shared publications Glenn M. Polin
Department of Cardiology, Division of Electrophysiology Ochsner Medical Center Louisiana New Orleans USA
9 shared publications- Robert M. Bober
Center for Healthcare Innovation, Sutter Health, San Francisco, CA
6 shared publications
Latest Publications
- 1 September 2026
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 19 (9)
When Science Is Sidelined: Implications of US Vaccine Policy Rollbacks for Electrophysiology and Cardiovascular Health
- 1 September 2026
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 19 (9)
When Science Is Sidelined: Implications of US Vaccine Policy Rollbacks for Electrophysiology and Cardiovascular Health
- Open Access
- 6 October 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Imaging Methods and Practice
- Vol. 3 (4)
The impact of fast vs. slow rubidium-82 infusion profile on precision and accuracy of PET myocardial blood flow perfusion metrics using a 1-tissue compartment model
Aims: Gould’s simplified retention model (GSRM), as implemented in the HeartSee software, demonstrates 10% same-day test-retest precision for PET-CT myocardial perfusion using a 50 or 20 mL/min Rb-82 infusions. HeartSee-GSRM also accurately quantifies resting myocardial blood flow (rMBF) in transmural scar (0.26 mL/min/g), aligning with reference standards. However, the impact for varying infusion rates on precision and accuracy of a 1-tissue compartment model (1-TCM) as implemented within 4DM software remains unclear. We assessed whether varying infusion rates of Rb-82 impacts 1-TCM precision and accuracy. Methods and results: Ninety-eight volunteers (Normals, Clinicals, and Infarcts), underwent 3D PET-CT stress testing. Three resting scans and two stress scans were performed with randomized fast (F) 50 mL/min or slow (S) 20 mL/min Rb-82 infusions. rMBF and stress MBF (sMBF) were calculated using 4DM software (1-TCM). Repeatability coefficients (RC) and coefficients of variance (COV) were calculated. Accuracy was assessed by comparing rMBF in infarcted myocardium (from 1-TCM and GSRM) against established reference standard for transmural myocardial scar (TMS). Fast infusion yielded better precision. RC was lower for F-F vs. S-S resting pairs (24.3% vs. 32.9%), and COV was lower (12.9% vs. 17.4%, P = 0.03). No difference in rMBF or sMBF was found between infusion rates (rMBF: 0.93 vs. 0.94 mL/min/g; sMBF: 2.23 vs. 2.30 mL/min/g). HeartSee GSRM produced rMBF values consistent with TMS (<0.30 mL/min/g), while 4DM 1-TCM overestimated rMBF (Fast: 0.79 ± 0.33; Slow: 0.82 ± 0.27 mL/min/g, P = 0.791), for both infusion profiles. Conclusion: Fast infusion improves 4DM 1-TCM precision, but 4DM 1-TCM overestimates rMBF in TMS regardless of infusion rate. HeartSee GSRM remains accurate and precise across profiles.
- 6 October 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Imaging Methods and Practice
- Vol. 3 (4)
Open AccessThe impact of fast vs. slow rubidium-82 infusion profile on precision and accuracy of PET myocardial blood flow perfusion metrics using a 1-tissue compartment model
Aims: Gould’s simplified retention model (GSRM), as implemented in the HeartSee software, demonstrates 10% same-day test-retest precision for PET-CT myocardial perfusion using a 50 or 20 mL/min Rb-82 infusions. HeartSee-GSRM also accurately quantifies resting myocardial blood flow (rMBF) in transmural scar (0.26 mL/min/g), aligning with reference standards. However, the impact for varying infusion rates on precision and accuracy of a 1-tissue compartment model (1-TCM) as implemented within 4DM software remains unclear. We assessed whether varying infusion rates of Rb-82 impacts 1-TCM precision and accuracy. Methods and results: Ninety-eight volunteers (Normals, Clinicals, and Infarcts), underwent 3D PET-CT stress testing. Three resting scans and two stress scans were performed with randomized fast (F) 50 mL/min or slow (S) 20 mL/min Rb-82 infusions. rMBF and stress MBF (sMBF) were calculated using 4DM software (1-TCM). Repeatability coefficients (RC) and coefficients of variance (COV) were calculated. Accuracy was assessed by comparing rMBF in infarcted myocardium (from 1-TCM and GSRM) against established reference standard for transmural myocardial scar (TMS). Fast infusion yielded better precision. RC was lower for F-F vs. S-S resting pairs (24.3% vs. 32.9%), and COV was lower (12.9% vs. 17.4%, P = 0.03). No difference in rMBF or sMBF was found between infusion rates (rMBF: 0.93 vs. 0.94 mL/min/g; sMBF: 2.23 vs. 2.30 mL/min/g). HeartSee GSRM produced rMBF values consistent with TMS (<0.30 mL/min/g), while 4DM 1-TCM overestimated rMBF (Fast: 0.79 ± 0.33; Slow: 0.82 ± 0.27 mL/min/g, P = 0.791), for both infusion profiles. Conclusion: Fast infusion improves 4DM 1-TCM precision, but 4DM 1-TCM overestimates rMBF in TMS regardless of infusion rate. HeartSee GSRM remains accurate and precise across profiles.
- 11 March 2025
- Published by Elsevier in Trends in Cardiovascular Medicine
- Vol. 35 (5) , 294-296
Editorial commentary: Atrial fibrillation in patients with cardiomyopathy – Protecting the vulnerable
- 11 March 2025
- Published by Elsevier in Trends in Cardiovascular Medicine
- Vol. 35 (5) , 294-296
Editorial commentary: Atrial fibrillation in patients with cardiomyopathy – Protecting the vulnerable
- Open Access
- 4 November 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (21) , e035610
Lipoprotein (a) Testing in Patients With Atherosclerotic Cardiovascular Disease in 5 Large US Health Systems
Background: Lipoprotein (a) is an independent risk factor for atherosclerotic cardiovascular disease. However, lipoprotein (a) testing remains variable and it is unclear what factors influence testing and if testing changes clinical management. Methods and Results: A retrospective study using electronic medical record data from 5 health systems identified an atherosclerotic cardiovascular disease cohort divided into those with and without a lipoprotein (a) test between 2019 and 2021. Baseline characteristics and lipid‐lowering therapy patterns were assessed. Multivariable regression modeling was used to determine factors associated with lipoprotein (a) testing. Among 595 684 patients with atherosclerotic cardiovascular disease, only 2587 (0.4%) were tested for lipoprotein (a). Those who were older or Black individuals were less likely to have lipoprotein (a) testing, while those with familial hypercholesterolemia, ischemic stroke/transient ischemic attack, peripheral artery disease, prior lipid‐lowering therapy, or low‐density lipoprotein cholesterol ≥130 mg/dL were more likely to be tested. Those with a lipoprotein (a) test, regardless of the lipoprotein (a) value, were more frequently initiated on any statin therapy (30.3% versus 10.6%, P < 0.001), ezetimibe (7.65% versus 0.8%, P < 0.001), or proprotein convertase substilisin/kexin type 9 inhibitor (6.7% versus 0.3%, P < 0.001) compared with those without a test. Those with an elevated lipoprotein (a) level more frequently initiated ezetimibe (11.5% versus 5.9%, P < 0.001) or proprotein convertase substilisin/kexin type 9 inhibitor (10.9% versus 4.8%, P < 0.001). Conclusions: Lipoprotein (a) testing in patients with atherosclerotic cardiovascular disease is infrequent, with evidence of disparities among older or Black individuals. Testing for lipoprotein (a), regardless of level, is associated with greater initiation of any lipid‐lowering therapy, while elevated lipoprotein (a) is associated with greater initiation of nonstatin lipid‐lowering therapy. There is a critical need for multidisciplinary and inclusive approaches to raise awareness for lipoprotein (a) testing, and its implications on management.
- 4 November 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (21) , e035610
Open AccessLipoprotein (a) Testing in Patients With Atherosclerotic Cardiovascular Disease in 5 Large US Health Systems
Background: Lipoprotein (a) is an independent risk factor for atherosclerotic cardiovascular disease. However, lipoprotein (a) testing remains variable and it is unclear what factors influence testing and if testing changes clinical management. Methods and Results: A retrospective study using electronic medical record data from 5 health systems identified an atherosclerotic cardiovascular disease cohort divided into those with and without a lipoprotein (a) test between 2019 and 2021. Baseline characteristics and lipid‐lowering therapy patterns were assessed. Multivariable regression modeling was used to determine factors associated with lipoprotein (a) testing. Among 595 684 patients with atherosclerotic cardiovascular disease, only 2587 (0.4%) were tested for lipoprotein (a). Those who were older or Black individuals were less likely to have lipoprotein (a) testing, while those with familial hypercholesterolemia, ischemic stroke/transient ischemic attack, peripheral artery disease, prior lipid‐lowering therapy, or low‐density lipoprotein cholesterol ≥130 mg/dL were more likely to be tested. Those with a lipoprotein (a) test, regardless of the lipoprotein (a) value, were more frequently initiated on any statin therapy (30.3% versus 10.6%, P < 0.001), ezetimibe (7.65% versus 0.8%, P < 0.001), or proprotein convertase substilisin/kexin type 9 inhibitor (6.7% versus 0.3%, P < 0.001) compared with those without a test. Those with an elevated lipoprotein (a) level more frequently initiated ezetimibe (11.5% versus 5.9%, P < 0.001) or proprotein convertase substilisin/kexin type 9 inhibitor (10.9% versus 4.8%, P < 0.001). Conclusions: Lipoprotein (a) testing in patients with atherosclerotic cardiovascular disease is infrequent, with evidence of disparities among older or Black individuals. Testing for lipoprotein (a), regardless of level, is associated with greater initiation of any lipid‐lowering therapy, while elevated lipoprotein (a) is associated with greater initiation of nonstatin lipid‐lowering therapy. There is a critical need for multidisciplinary and inclusive approaches to raise awareness for lipoprotein (a) testing, and its implications on management.
- Open Access
- 28 October 2024
- Published by Elsevier in JACC: Advances
- Vol. 3 (12) , 101370
Participant Engagement and Preference Study for Clinical Outcomes Associated With Atrial Fibrillation
- 28 October 2024
- Published by Elsevier in JACC: Advances
- Vol. 3 (12) , 101370
Open AccessParticipant Engagement and Preference Study for Clinical Outcomes Associated With Atrial Fibrillation
- Open Access
- 18 October 2024
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 41, 102059
Fast vs slow rubidium-82 infusion profiles and test-retest precision of myocardial perfusion using contemporary 3D cardiac analog positron emission tomography-computed tomography imaging
- 18 October 2024
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 41, 102059
Open AccessFast vs slow rubidium-82 infusion profiles and test-retest precision of myocardial perfusion using contemporary 3D cardiac analog positron emission tomography-computed tomography imaging
- Open Access
Lipoprotein(a) testing in Patients with Atherosclerotic Cardiovascular Disease in Five Large U.S. Health Systems
Introduction Lipoprotein (a) [Lp(a)] is an independent, causal risk factor for atherosclerotic cardiovascular disease (ASCVD). However, testing patterns remain variable and it is unclear what patient level factors are associated with Lp(a) testing, and if testing changes clinical management. Methods A retrospective study using electronic medical record data from five health systems in the CardioHealth Alliance identified an ASCVD cohort that was divided into those with a Lp(a) test and those without a Lp(a) test between 2019-2021. Baseline characteristics and initiation of lipid lowering therapy (LLT) was assessed. Multivariable regression modeling was used to determine factors associated with Lp(a) testing. Results Among 595,684 ASCVD patients, only 2,587 (0.4%) were tested for Lp(a) between 2019 and 2021. In adjusted models, those who were older or Black were less likely to have Lp(a) testing, while those with familial hypercholesterolemia, ischemic stroke/TIA, PAD, prior LLT, or LDL-C ≥130mg/dL were more likely to be tested. Those with a Lp(a) test, regardless of the Lp(a) value, were more frequently initiated on any statin therapy (30.3% vs. 10.6%, pConclusions Lp(a) testing in ASCVD patients is infrequent, with evidence of disparities among older or Black individuals. Testing for Lp(a), regardless of level, is associated with greater initiation of any LLT, while elevated Lp(a) is associated with greater initiation of non-statin LLT. Overall, initiation of LLT remained low, despite guideline indications for LLT in ASCVD patients. There is a critical need for multidisciplinary and inclusive approaches to raise awareness for Lp(a) testing and its implications on management.
Open AccessLipoprotein(a) testing in Patients with Atherosclerotic Cardiovascular Disease in Five Large U.S. Health Systems
Introduction Lipoprotein (a) [Lp(a)] is an independent, causal risk factor for atherosclerotic cardiovascular disease (ASCVD). However, testing patterns remain variable and it is unclear what patient level factors are associated with Lp(a) testing, and if testing changes clinical management. Methods A retrospective study using electronic medical record data from five health systems in the CardioHealth Alliance identified an ASCVD cohort that was divided into those with a Lp(a) test and those without a Lp(a) test between 2019-2021. Baseline characteristics and initiation of lipid lowering therapy (LLT) was assessed. Multivariable regression modeling was used to determine factors associated with Lp(a) testing. Results Among 595,684 ASCVD patients, only 2,587 (0.4%) were tested for Lp(a) between 2019 and 2021. In adjusted models, those who were older or Black were less likely to have Lp(a) testing, while those with familial hypercholesterolemia, ischemic stroke/TIA, PAD, prior LLT, or LDL-C ≥130mg/dL were more likely to be tested. Those with a Lp(a) test, regardless of the Lp(a) value, were more frequently initiated on any statin therapy (30.3% vs. 10.6%, pConclusions Lp(a) testing in ASCVD patients is infrequent, with evidence of disparities among older or Black individuals. Testing for Lp(a), regardless of level, is associated with greater initiation of any LLT, while elevated Lp(a) is associated with greater initiation of non-statin LLT. Overall, initiation of LLT remained low, despite guideline indications for LLT in ASCVD patients. There is a critical need for multidisciplinary and inclusive approaches to raise awareness for Lp(a) testing and its implications on management.
- 3 January 2024
- Published by Elsevier in The American Journal of Cardiology
- Vol. 214, 182-183
Ohm My Goodness! Thoracic Impedance, Its Predictors, and How It Relates to Cardioversion
- 3 January 2024
- Published by Elsevier in The American Journal of Cardiology
- Vol. 214, 182-183
Ohm My Goodness! Thoracic Impedance, Its Predictors, and How It Relates to Cardioversion
- 7 November 2023
- Published by Elsevier in Journal of Cardiothoracic and Vascular Anesthesia
- Vol. 38 (1) , 67-72
Use of a New Standardized Unfractionated Heparin Protocol for Left-Sided Ablation Procedures Improves Time in the Therapeutic ACT Range
- 7 November 2023
- Published by Elsevier in Journal of Cardiothoracic and Vascular Anesthesia
- Vol. 38 (1) , 67-72
Use of a New Standardized Unfractionated Heparin Protocol for Left-Sided Ablation Procedures Improves Time in the Therapeutic ACT Range
- Open Access
- 18 October 2023
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 10 (10) , 434
Gender-Based Clinical, Therapeutic Strategies and Prognosis Differences in Atrial Fibrillation
Background: There are limited data on gender-based differences in atrial fibrillation (AF) treatment and prognosis. We aimed to examine gender-related differences in medical attention in an emergency department (ED) and follow-up (FU) among patients diagnosed with an AF episode and to determine whether there are gender-related differences in clinical characteristics, therapeutic strategies, and long-term adverse events in this population. Methods: We performed a retrospective observational study of patients who presented to a tertiary hospital ER for AF from 2010 to 2015, with a minimum FU of one year. Data on medical attention received, mortality, and other adverse outcomes were collected and analyzed. Results: Among the 2013 patients selected, 1232 (60%) were female. Women were less likely than men to be evaluated by a cardiologist during the ED visit (11.5% vs. 16.6%, p = 0.001) and were less likely to be admitted (5.9% vs. 9.5%, p < 0.05). Electrical cardioversion was performed more frequently in men, both during the first episode (3.4% vs. 1.2%, p = 0.001) and during FU (15.9% vs. 10.6%, p < 0.001), despite a lower AF recurrence rate in women (9.9% vs. 18.1%). During FU, women had more hospitalizations for heart failure (26.2% vs. 16.1%, p < 0.001). Conclusions: In patients with AF, although there were no gender differences in mortality, there were significant differences in clinical outcomes, medical attention received, and therapeutic strategies. Women underwent fewer attempts at cardioversion, had a lower probability of being evaluated by cardiologists, and showed a higher probability of hospitalization for heart failure. Being alert to these inequities should facilitate the adoption of measures to correct them.
- 18 October 2023
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 10 (10) , 434
Open AccessGender-Based Clinical, Therapeutic Strategies and Prognosis Differences in Atrial Fibrillation
Background: There are limited data on gender-based differences in atrial fibrillation (AF) treatment and prognosis. We aimed to examine gender-related differences in medical attention in an emergency department (ED) and follow-up (FU) among patients diagnosed with an AF episode and to determine whether there are gender-related differences in clinical characteristics, therapeutic strategies, and long-term adverse events in this population. Methods: We performed a retrospective observational study of patients who presented to a tertiary hospital ER for AF from 2010 to 2015, with a minimum FU of one year. Data on medical attention received, mortality, and other adverse outcomes were collected and analyzed. Results: Among the 2013 patients selected, 1232 (60%) were female. Women were less likely than men to be evaluated by a cardiologist during the ED visit (11.5% vs. 16.6%, p = 0.001) and were less likely to be admitted (5.9% vs. 9.5%, p < 0.05). Electrical cardioversion was performed more frequently in men, both during the first episode (3.4% vs. 1.2%, p = 0.001) and during FU (15.9% vs. 10.6%, p < 0.001), despite a lower AF recurrence rate in women (9.9% vs. 18.1%). During FU, women had more hospitalizations for heart failure (26.2% vs. 16.1%, p < 0.001). Conclusions: In patients with AF, although there were no gender differences in mortality, there were significant differences in clinical outcomes, medical attention received, and therapeutic strategies. Women underwent fewer attempts at cardioversion, had a lower probability of being evaluated by cardiologists, and showed a higher probability of hospitalization for heart failure. Being alert to these inequities should facilitate the adoption of measures to correct them.